BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abraldes J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-8. [DOI: 10.1053/jhep.2003.50133] [Cited by in Crossref: 362] [Cited by in F6Publishing: 300] [Article Influence: 19.1] [Reference Citation Analysis]
Number Citing Articles
1 Poza Cordon J, Froilan Torres C, Burgos García A, Gea Rodriguez F, Suárez de Parga JM. Endoscopic management of esophageal varices. Clinical manifestations and management 2012; 4(7): 312-322 [PMID: 22816012 DOI: 10.4253/wjge.v4.i7.312] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
2 Agarwal S, Sharma S, Anand A, Gunjan D, Saraya A. Liver stiffness assessment as an alternative to hepatic venous pressure gradient for predicting rebleed after acute variceal bleed: A proof-of-concept study. JGH Open 2021;5:73-80. [PMID: 33490616 DOI: 10.1002/jgh3.12449] [Reference Citation Analysis]
3 Huet PM, Vincent C, Deslaurier J, Coté J, Matsutami S, Boileau R, Huet-van Kerckvoorde J. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology. 2008;135:1552-1560. [PMID: 18722374 DOI: 10.1053/j.gastro.2008.07.019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
4 Ravaioli F, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, Azzaroli F, Brillanti S, Mazzella G, Festi D. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. World J Hepatol 2018; 10(10): 731-742 [PMID: 30386466 DOI: 10.4254/wjh.v10.i10.731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
5 Villanueva C, Balanzó J. Variceal Bleeding: Pharmacological Treatment and Prophylactic Strategies. Drugs 2008;68:2303-24. [DOI: 10.2165/0003495-200868160-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
6 Thalheimer U, Bellis L, Puoti C, Burroughs AK. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No. Eur J Intern Med 2011;22:5-7. [PMID: 21238884 DOI: 10.1016/j.ejim.2010.12.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
7 Kim BK, Kim do Y, Han KH, Park JY, Kim JK, Paik YH, Lee KS, Chon CY, Ahn SH. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol. 2011;106:1654-1652, 1730. [PMID: 21691339 DOI: 10.1038/ajg.2011.160] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
8 Grangé JD, Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice. Eur J Gastroenterol Hepatol 2004;16:567-70. [PMID: 15167158 DOI: 10.1097/00042737-200406000-00009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
9 Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42 Suppl:S85-S92. [PMID: 15777576 DOI: 10.1016/j.jhep.2004.12.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]
10 Stankovic Z, Frydrychowicz A, Csatari Z, Panther E, Deibert P, Euringer W, Kreisel W, Russe M, Bauer S, Langer M. MR-based visualization and quantification of three-dimensional flow characteristics in the portal venous system. J Magn Reson Imaging. 2010;32:466-475. [PMID: 20677279 DOI: 10.1002/jmri.22248] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
11 Corbett C, Mangat K, Olliff S, Tripathi D. The role of Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of variceal hemorrhage. Liver Int. 2012;32:1493-1504. [PMID: 22928699 DOI: 10.1111/j.1478-3231.2012.02861.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
12 Thalheimer U, Triantos C, Goulis J, Burroughs AK. Management of varices in cirrhosis. Expert Opin Pharmacother 2011;12:721-35. [PMID: 21269241 DOI: 10.1517/14656566.2011.537258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Dell'era A, Bosch J. Review article: the relevance of portal pressure and other risk factors in acute gastro-oesophageal variceal bleeding. Aliment Pharmacol Ther. 2004;20 Suppl 3:8-15; discussion 16. [PMID: 15335392 DOI: 10.1111/j.1365-2036.2004.02109.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
14 Bosch J, Garcia-tsao G. Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is…. Hepatology 2009;50:674-7. [DOI: 10.1002/hep.23164] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
15 D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231. [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013] [Cited by in Crossref: 1547] [Cited by in F6Publishing: 1305] [Article Influence: 91.0] [Reference Citation Analysis]
16 Lo GH, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA, Yu HC, Hsu PI, Lai KH. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology. 2008;48:580-587. [PMID: 18666235 DOI: 10.1002/hep.22358] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
17 Abid S, Ali S, Baig MA, Waheed AA. Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc 2015; 7(5): 532-539 [PMID: 25992192 DOI: 10.4253/wjge.v7.i5.532] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Turnes J, Garcia-pagan JC, Bosch J. What else we need. In: Groszmann RJ, Bosch J, editors. Portal Hypertension in the 21st Century. Dordrecht: Springer Netherlands; 2004. pp. 349-60. [DOI: 10.1007/978-94-007-1042-9_35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Abraldes JG, Trebicka J, Chalasani N, D’amico G, Rockey DC, Shah VH, Bosch J, Garcia-tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension: Hepatology. Hepatology 2019;69:1287-99. [DOI: 10.1002/hep.30314] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
20 Northup PG, Henry ZH. Editorial: Beta-blockers and the prevention of decompensation in cirrhosis: worth the trouble. Am J Gastroenterol 2012;107:428-30. [PMID: 22388023 DOI: 10.1038/ajg.2011.466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Lopez-mendez E, Avila-escobedo L. Pregnancy and portal hypertension a pathology view of physiologic changes. Annals of Hepatology 2006;5:219-23. [DOI: 10.1016/s1665-2681(19)32016-2] [Cited by in Crossref: 12] [Article Influence: 0.8] [Reference Citation Analysis]
22 Groszmann R, Vorobioff JD, Gao H. Measurement of portal pressure: when, how, and why to do it. Clin Liver Dis 2006;10:499-512, viii. [PMID: 17162225 DOI: 10.1016/j.cld.2006.08.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
23 Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol 2005;43:637-44. [PMID: 16083986 DOI: 10.1016/j.jhep.2005.04.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
24 Bittencourt PL, Farias AQ, Strauss E, Mattos AA; Pannel of the 1st Brazilian Consensus of Variceal Bleeding, Brazilian Society of Hepatology. Variceal bleeding: consensus meeting report from the Brazilian Society of Hepatology. Arq Gastroenterol. 2010;47:202-216. [PMID: 20721469 DOI: 10.1590/s0004-28032010000200017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
25 Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 2017;52:1008-15. [PMID: 28532189 DOI: 10.1080/00365521.2017.1329456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Kumar M, Sakhuja P, Kumar A, Manglik N, Choudhury A, Hissar S, Rastogi A, Sarin SK. Histological subclassification of cirrhosis based on histological-haemodynamic correlation. Aliment Pharmacol Ther. 2008;27:771-779. [PMID: 18284653 DOI: 10.1111/j.1365-2036.2008.03653.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
27 Kim MY, Baik SK, Suk KT, Yea CJ, Lee IY, Kim JW, Cha SH, Kim YJ, Um SH, Han KH. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea]. Korean J Hepatol. 2008;14:150-158. [PMID: 18617762 DOI: 10.3350/kjhep.2008.14.2.150] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
28 Bosch J, Abraldes JG. Variceal bleeding: pharmacological therapy. Dig Dis 2005;23:18-29. [PMID: 15920322 DOI: 10.1159/000084722] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
29 Garcia-Tsao G. Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol 2005;22:278-86. [PMID: 21326706 DOI: 10.1055/s-2005-925554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
30 Bosch J, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, de la Peña J, Escorsell A, García-pagán JC, Genescà J, Hernández-guerra M, Ripoll C, Planas R, Villanueva C. Hipertensión portal: recomendaciones para su evaluación y tratamiento. Gastroenterología y Hepatología 2012;35:421-50. [DOI: 10.1016/j.gastrohep.2012.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
31 Nishio T, Taura K, Nakamura N, Seo S, Yasuchika K, Kaido T, Okajima H, Hatano E, Uemoto S. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery 2018;163:264-9. [PMID: 29167018 DOI: 10.1016/j.surg.2017.09.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
32 Manousou P, Samonakis D, Cholongitas E, Patch D, O'beirne J, Dhillon AP, Rolles K, Mccormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy: Randomized Immunosuppression for Recurrent HCV. Liver Transpl 2009;15:1783-91. [DOI: 10.1002/lt.21907] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
33 Nietsch HH. Management of Portal Hypertension: . Journal of Clinical Gastroenterology 2005;39:232-6. [DOI: 10.1097/01.mcg.0000152783.22266.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
34 Berzigotti A, Rinaldi MF, Magalotti D, Morelli MC, Zappoli P, Andreone P, Rossi C, Zoli M. Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. Journal of Hepatology 2006;44:310-6. [DOI: 10.1016/j.jhep.2005.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
35 Ma R, Chen J, Liang Y, Lin S, Zhu L, Liang X, Cai X. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes. Biomedicine & Pharmacotherapy 2017;88:459-68. [DOI: 10.1016/j.biopha.2017.01.107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
36 Villanueva C, Colomo A, Aracil C, Guarner C. Current endoscopic therapy of variceal bleeding. Best Pract Res Clin Gastroenterol. 2008;22:261-278. [PMID: 18346683 DOI: 10.1016/j.bpg.2007.11.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
37 Guo H, Xiao J, Wang Y, Zhang M, Zhuge Y, Zhang F. Increase in Free Hepatic Venous Pressure Response to Beta-Blockers Predicts Variceal Bleeding in Cirrhotic Patients. Biomed Res Int 2021;2021:5587566. [PMID: 33997022 DOI: 10.1155/2021/5587566] [Reference Citation Analysis]
38 Vanbiervliet G, Pomier-Layrargues G, Huet PM. [Invasive diagnosis of portal hypertension in cirrhosis: a critical evaluation of the hepatic venous pressure gradient measurement]. Gastroenterol Clin Biol. 2005;29:988-996. [PMID: 16435504 DOI: 10.1016/s0399-8320(05)88171-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007;132:709-719. [PMID: 17258737 DOI: 10.1053/j.gastro.2006.12.041] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
40 Lemmers A, Evrard S, Demetter P, Verset G, Gossum AV, Adler M, Devière J, Moine OL. Gastrointestinal polypoid lesions: a poorly known endoscopic feature of portal hypertension. United European Gastroenterol J. 2014;2:189-196. [PMID: 25360302 DOI: 10.1177/2050640614529108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
41 Yan SP, Wu H, Wang GC, Chen Y, Zhang CQ, Zhu Q. A new model combining the liver/spleen volume ratio and classification of varices predicts HVPG in hepatitis B patients with cirrhosis. Eur J Gastroenterol Hepatol. 2015;27:335-343. [PMID: 25563138 DOI: 10.1097/meg.0000000000000269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
42 Garcia-tsao G. Portal hypertension: . Current Opinion in Gastroenterology 2005;21:313-22. [DOI: 10.1097/01.mog.0000158110.13722.e0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
43 Fedosina EA, Byeverov AO, Bogomolov PO, Staroverova NP. [Some practical issues in the management of patients with decompensated liver cirrhosis]. Ter Arkh 2019;91:148-54. [PMID: 32598767 DOI: 10.26442/00403660.2019.08.000391] [Reference Citation Analysis]
44 Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, Bruguera M, García-Valdecasas JC, Bosch J. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43:492-499. [PMID: 16496308 DOI: 10.1002/hep.21090] [Cited by in Crossref: 220] [Cited by in F6Publishing: 199] [Article Influence: 13.8] [Reference Citation Analysis]
45 Albillos A, Bañares R, González M, Ripoll C, Gonzalez R, Catalina MV, Molinero LM. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102:1116-26. [PMID: 17391317 DOI: 10.1111/j.1572-0241.2007.01191.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 75] [Article Influence: 6.4] [Reference Citation Analysis]
46 Burroughs AK. The Hepatic Artery, Portal Venous System and Portal Hypertension: The Hepatic Veins and Liver in Circulatory Failure. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 152-209. [DOI: 10.1002/9781444341294.ch9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
47 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310-335. [PMID: 27786365 DOI: 10.1002/hep.28906] [Cited by in Crossref: 713] [Cited by in F6Publishing: 537] [Article Influence: 118.8] [Reference Citation Analysis]
48 Semmler G, Scheiner B, Schwabl P, Bucsics T, Paternostro R, Chromy D, Stättermayer AF, Trauner M, Mandorfer M, Ferlitsch A, Reiberger T. The impact of hepatic steatosis on portal hypertension. PLoS One 2019;14:e0224506. [PMID: 31693695 DOI: 10.1371/journal.pone.0224506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Gomez EV, Gonzalez AT, Bertot LC, Yasells Garcia A, Rodriguez YS, Perez YM. Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One 2014;9:e95736. [PMID: 24755710 DOI: 10.1371/journal.pone.0095736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
50 Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, Wong WW, Ma MM. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int. 2009;29:1110-1115. [PMID: 19490420 DOI: 10.1111/j.1478-3231.2009.02020.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
51 Abraldes JG, Sarlieve P, Tandon P. Measurement of portal pressure. Clin Liver Dis. 2014;18:779-792. [PMID: 25438283 DOI: 10.1016/j.cld.2014.07.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
52 Parker R. Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Clin Liver Dis. 2014;18:319-334. [PMID: 24679497 DOI: 10.1016/j.cld.2013.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
53 Qamar AA. Compensated cirrhosis, same outcomes no matter which continent. Hepatology 2013;58:1511-3. [PMID: 23729349 DOI: 10.1002/hep.26527] [Reference Citation Analysis]
54 D’Amico M, Mejías M, García-Pras E, Abraldes JG, García-Pagán JC, Fernández M, Bosch J. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1191-G1198. [PMID: 22403792 DOI: 10.1152/ajpgi.00252.2011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
55 Fernández J, Tandon P, Mensa J, Garcia-tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology 2016;63:2019-31. [DOI: 10.1002/hep.28330] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 16.0] [Reference Citation Analysis]
56 Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García–pagán JC, Bosch J. Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. Gastroenterology 2009;136:1651-8. [DOI: 10.1053/j.gastro.2009.01.043] [Cited by in Crossref: 259] [Cited by in F6Publishing: 220] [Article Influence: 19.9] [Reference Citation Analysis]
57 D’Amico G. The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opin Pharmacother. 2004;5:349-360. [PMID: 14996631 DOI: 10.1517/14656566.5.2.349] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
58 Lin HC, Huang YT, Yang YY, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. J Gastroenterol Hepatol. 2014;29:1073-1082. [PMID: 24325631 DOI: 10.1111/jgh.12480] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
59 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
60 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Gopi S, Mohta S, Saraya A. Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort. J Clin Exp Hepatol 2021;11:443-52. [PMID: 34276151 DOI: 10.1016/j.jceh.2020.11.001] [Reference Citation Analysis]
61 Kawamura E, Habu D, Hayashi T, Oe A, Kotani J, Ishizu H, Torii K, Kawabe J, Fukushima W, Tanaka T, Nishiguchi S, Shiomi S. Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. World J Gastroenterol 2005; 11(25): 3882-3886 [PMID: 15991287 DOI: 10.3748/wjg.v11.i25.3882] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
62 Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-radosavljevic M; Vienna Hepatic Hemodynamic Lab. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 2012;47:561-8. [DOI: 10.1007/s00535-011-0517-4] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
63 La Mura V, Salerno F. Therapy of the refractory ascites: Total paracentesis vs. TIPS. Gastroenterología y Hepatología 2016;39:477-80. [DOI: 10.1016/j.gastrohep.2015.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51:2214-2218. [PMID: 20513005 DOI: 10.1002/hep.23689] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
65 Sánchez-conde M, Pérez-latorre L, Rincón D, Miralles P, Catalina M, López JC, Bañares R, Berenguer J. Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015;69:e142-4. [DOI: 10.1097/qai.0000000000000639] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, Dhali GK, Chowdhury A. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol. 2018;30:54-59. [PMID: 29099421 DOI: 10.1097/meg.0000000000001006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
67 Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24:823-831. [PMID: 28295923 DOI: 10.1111/jvh.12706] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 14.2] [Reference Citation Analysis]
68 Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9(5): 270-277 [PMID: 28261384 DOI: 10.4254/wjh.v9.i5.270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
69 Mookerjee RP. Acute-on-chronic liver failure: the liver and portal haemodynamics: . Current Opinion in Critical Care 2011;17:170-6. [DOI: 10.1097/mcc.0b013e328344a076] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
70 Heebøll S, Villadsen GE, Aagaard NK, Grønbæk H, Vilstrup H, Keiding S. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. Scand J Gastroenterol. 2013;48:969-973. [PMID: 23755897 DOI: 10.3109/00365521.2013.805811] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
71 Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010;53:1135-45. [PMID: 20850887 DOI: 10.1016/j.jhep.2010.08.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
72 Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-radosavljevic M; for the Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003;38:1043-50. [DOI: 10.1002/hep.1840380431] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
73 Hernández-gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C. Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-Blockers. American Journal of Gastroenterology 2012;107:418-27. [DOI: 10.1038/ajg.2011.456] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 8.7] [Reference Citation Analysis]
74 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Role of band ligation for secondary prophylaxis of variceal bleeding. World J Gastroenterol 2018; 24(26): 2902-2914 [PMID: 30018485 DOI: 10.3748/wjg.v24.i26.2902] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
75 Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005;25:1079-90. [PMID: 16343056 DOI: 10.1111/j.1478-3231.2005.01163.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 5.1] [Reference Citation Analysis]
76 Paik YH. [The relation between hepatic venous pressure gradient and complications of liver cirrhosis]. Korean J Hepatol 2008;14:136-8. [PMID: 18617760 DOI: 10.3350/kjhep.2008.14.2.136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Jafri S, Gordon SC. Care of the Cirrhotic Patient. Infectious Disease Clinics of North America 2012;26:979-94. [DOI: 10.1016/j.idc.2012.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
78 Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488. [PMID: 17681169 DOI: 10.1053/j.gastro.2007.05.024] [Cited by in Crossref: 643] [Cited by in F6Publishing: 527] [Article Influence: 42.9] [Reference Citation Analysis]
79 Giannini EG. Pro: Cirrhotic Patients With Small Esophageal Varices Should Undergo Primary Prophylaxis. Am J Gastroenterol 2009;104:2132-4. [DOI: 10.1038/ajg.2009.448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Mura VL, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window. World J Gastroenterol 2015; 21(8): 2265-2268 [PMID: 25741132 DOI: 10.3748/wjg.v21.i8.2265] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450-455. [PMID: 23216382 DOI: 10.1111/jgh.12070] [Cited by in Crossref: 121] [Cited by in F6Publishing: 114] [Article Influence: 13.4] [Reference Citation Analysis]
82 Silva-junior G, Turon F, Baiges A, Cerda E, García-criado Á, Blasi A, Torres F, Hernandez-gea V, Bosch J, Garcia-pagan JC. Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. Gastroenterology 2017;152:1358-65. [DOI: 10.1053/j.gastro.2017.01.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
83 Thalheimer U, Bosch J, Burroughs AK. An apology for beta blockers. J Hepatol 2014;61:450-1. [PMID: 24768757 DOI: 10.1016/j.jhep.2014.03.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
84 Puente A, Hernández-gea V, Graupera I, Roque M, Colomo A, Poca M, Aracil C, Gich I, Guarner C, Villanueva C. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int 2014;34:823-33. [DOI: 10.1111/liv.12452] [Cited by in Crossref: 68] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
85 Burza MA, Marschall HU, Napoleone L, Molinaro A. The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight? Pharmacol Res 2017;119:20-6. [PMID: 28099882 DOI: 10.1016/j.phrs.2017.01.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
86 Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15:308. [PMID: 23314828 DOI: 10.1007/s11894-012-0308-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
87 D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611-1624. [PMID: 17101332 DOI: 10.1053/j.gastro.2006.09.013] [Cited by in Crossref: 333] [Cited by in F6Publishing: 262] [Article Influence: 20.8] [Reference Citation Analysis]
88 Villanueva C, López-balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, Guarner C, Balanzó J. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. Journal of Hepatology 2004;40:757-65. [DOI: 10.1016/j.jhep.2004.01.017] [Cited by in Crossref: 124] [Cited by in F6Publishing: 100] [Article Influence: 6.9] [Reference Citation Analysis]
89 Bellot P, Jara Pérez López N, Martínez Moreno B, Such J. [Current problems in the prevention and treatment of infections in patients with cirrhosis]. Gastroenterol Hepatol. 2010;33:729-740. [PMID: 20444525 DOI: 10.1016/j.gastrohep.2010.02.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
90 Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology. 2009;137:119-128. [PMID: 19344721 DOI: 10.1053/j.gastro.2009.03.048] [Cited by in Crossref: 140] [Cited by in F6Publishing: 108] [Article Influence: 10.8] [Reference Citation Analysis]
91 Hu T, Stock S, Hong W, Chen Y. Modified 'sandwich' injection with or without ligation for variceal bleeding in patients with both esophageal and gastric varices: a retrospective cohort study. Scand J Gastroenterol 2020;55:1219-24. [PMID: 32780613 DOI: 10.1080/00365521.2020.1803959] [Reference Citation Analysis]
92 Tandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience. Liver Int 2016;36:1160-6. [PMID: 26763558 DOI: 10.1111/liv.13065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
93 Dittrich S, Mattos AA, Mattos AZ, Alves AV, Araújo FB. [Relationship between portal pressure gradient and ascites in cirrhotic patients]. Arq Gastroenterol. 2010;47:174-177. [PMID: 20721463 DOI: 10.1590/S0004-28032010000200011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Bosch J. Soft technique, hard end-points. Journal of Hepatology 2011;55:955-6. [DOI: 10.1016/j.jhep.2011.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
95 Bosch J. Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol. 2007;41 Suppl 3:S247-S253. [PMID: 17975472 DOI: 10.1097/mcg.0b013e3181572357] [Cited by in Crossref: 98] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
96 Bellot P, García-Pagán JC, Abraldes JG, Bosch J. Primary prophylaxis of esophageal variceal bleeding in cirrhosis. Gastroenterol Clin Biol. 2008;32:532-540. [PMID: 18456445 DOI: 10.1016/j.gcb.2008.03.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
97 García-pagán JC, Bosch J. Prevention of variceal rebleeding. The Lancet 2003;361:2245. [DOI: 10.1016/s0140-6736(03)13750-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
98 Wani ZA, Baht RA, Bhadoria AS, Maiwall R, Majeed Y, Khan AA, Zargar SA, Shah MA, Khan KM. After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis? Saudi J Gastroenterol. 2015;21:278-283. [PMID: 26458853 DOI: 10.4103/1319-3767.164207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Miñano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am 2010;39:681-95. [PMID: 20951924 DOI: 10.1016/j.gtc.2010.08.015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
100 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
101 Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol 2014; 20(45): 16996-17010 [PMID: 25493012 DOI: 10.3748/wjg.v20.i45.16996] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
102 Kawaratani H, Fukui H, Yoshiji H. Treatment for cirrhotic ascites. Hepatol Res. 2017;47:166-177. [PMID: 27363974 DOI: 10.1111/hepr.12769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
103 Bruha R, Vitek L, Petrtyl J, Lenicek M, Urbanek P, Zelenka J, Jachymova M, Svestka T, Kalab M, Dousa M, Marecek Z. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scandinavian Journal of Gastroenterology 2009;41:1454-63. [DOI: 10.1080/00365520600780403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
104 Stewart CA, Smith GE. Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol. 2007;4:677-685. [PMID: 18043677 DOI: 10.1038/ncpgasthep0999] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
105 Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009;49:1245-1256. [PMID: 19137587 DOI: 10.1002/hep.22758] [Cited by in Crossref: 231] [Cited by in F6Publishing: 205] [Article Influence: 17.8] [Reference Citation Analysis]
106 Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, Marrero JM, Buceta E, Sánchez J, Castellot A. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40:793-801. [PMID: 15382120 DOI: 10.1002/hep.1840400408] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
107 Thalheimer U, Mela M, Patch D, Burroughs AK. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. Gut. 2004;53:143-148. [PMID: 14684589 DOI: 10.1136/gut.53.1.143] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
108 Abraldes JG, Angermayr B, Bosch J. The management of portal hypertension. Clin Liver Dis 2005;9:685-713, vii. [PMID: 16207571 DOI: 10.1016/j.cld.2005.08.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
109 Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911-921. [PMID: 23262249 DOI: 10.1016/j.jhep.2012.12.011] [Cited by in Crossref: 184] [Cited by in F6Publishing: 160] [Article Influence: 18.4] [Reference Citation Analysis]
110 Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286-2298. [PMID: 24259407 DOI: 10.1002/hep.26939] [Cited by in Crossref: 153] [Cited by in F6Publishing: 151] [Article Influence: 19.1] [Reference Citation Analysis]
111 La Mura V, Abraldes JG, Berzigotti A, Erice E, Flores-Arroyo A, García-Pagán JC, Bosch J. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. Hepatology. 2010;51:2108-2116. [PMID: 20512998 DOI: 10.1002/hep.23612] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
112 Kim BK, Ahn SH, Han K, Park JY, Han MS, Jo JH, Kim JK, Lee KS, Chon CY, Kim DY. Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion 2012;86:264-72. [DOI: 10.1159/000341507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
113 Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-radosavljevic M, Ferlitsch A. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther 2018;47:86-94. [DOI: 10.1111/apt.14377] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
114 Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, Marchiori RC, Rezende GF. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial. Dig Liver Dis. 2015;47:957-963. [PMID: 26321186 DOI: 10.1016/j.dld.2015.07.156] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 7.1] [Reference Citation Analysis]
115 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 520] [Article Influence: 165.0] [Reference Citation Analysis]
116 Funakoshi N, Duny Y, Valats JC, Ségalas-Largey F, Flori N, Bismuth M, Daurès JP, Blanc P. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. Ann Hepatol 2012;11:369-83. [PMID: 22481457 [PMID: 22481457 DOI: 10.1016/s1665-2681(19)30934-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 1] [Article Influence: 3.4] [Reference Citation Analysis]
117 Rincon D, Lo Iacono O, Ripoll C, Gomez-Camarero J, Salcedo M, Catalina MV, Hernando A, Clemente G, Matilla A, Nuñez O, Bañares R. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther 2007;25:841-8. [PMID: 17373923 DOI: 10.1111/j.1365-2036.2007.03258.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
118 Villanueva C, Aracil C, Colomo A, Lopez-Balaguer JM, Piqueras M, Gonzalez B, Torras X, Guarner C, Balanzo J. Clinical trial: A randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther. 2009;29:397-408. [PMID: 19006538 DOI: 10.1111/j.1365-2036.2008.03880.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
119 Diago M. [Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?]. Gastroenterol Hepatol 2007;30:85-92. [PMID: 17335716 DOI: 10.1157/13099273] [Reference Citation Analysis]
120 Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: a critical reappraisal. Hepatology 2004;39:286-90. [PMID: 14767978 DOI: 10.1002/hep.20061] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
121 Song Q, Zeng M, Chen C, Ma J, Yun H, Rao S, Yao X. Non–Contrast-Enhanced Magnetic Resonance Angiography Using T2-Weighted 3-Dimensional Fat-Suppressed Turbo Spin Echo (SPACE): Diagnostic Performance and Comparison With Contrast-Enhanced Magnetic Resonance Angiography Using Volume Interpolated Breath-Hold Examination in the Detection of Portosystemic and Portohepatic Collaterals. Journal of Computer Assisted Tomography 2012;36:675-80. [DOI: 10.1097/rct.0b013e31826999df] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
122 Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol 2012; 18(11): 1166-1175 [PMID: 22468079 DOI: 10.3748/wjg.v18.i11.1166] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 70] [Article Influence: 8.1] [Reference Citation Analysis]
123 Senzolo M, Cholongitas E, Marelli L, Thalheimer U, Patch D, Burroughs AK. The Low Incidence of Bacterial Infections Could Be a Protective Factor Against Variceal Bleeding Per Se in Hemodynamic Responders to Propranolol. Am J Gastroenterology 2006;101:2436-7. [DOI: 10.1111/j.1572-0241.2006.00742_5.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
124 Vorobioff JD, Abraldes JG, Groszmann RJ. Hepatic venous pressure gradient: the facts. In: Groszmann RJ, Bosch J, editors. Portal Hypertension in the 21st Century. Dordrecht: Springer Netherlands; 2004. pp. 309-22. [DOI: 10.1007/978-94-007-1042-9_32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Lay CS, Tsai YT, Lee FY, Lai YL, Yu CJ, Chen CB, Peng CY. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol. 2006;21:413-419. [PMID: 16509867 DOI: 10.1111/j.1440-1746.2005.04071.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
126 Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One 2017;12:e0169310. [PMID: 28146577 DOI: 10.1371/journal.pone.0169310] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
127 de Souza AR, La Mura V, Berzigotti A, García-Pagán JC, Abraldes JG, Bosch J. Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis. Hepatology 2015;62:1840-6. [PMID: 26340692 DOI: 10.1002/hep.28151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
128 Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749-1761. [PMID: 24480518 DOI: 10.1016/s0140-6736(14)60121-5] [Cited by in Crossref: 801] [Cited by in F6Publishing: 395] [Article Influence: 100.1] [Reference Citation Analysis]
129 Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634-1641. [PMID: 23250049 DOI: 10.1136/gutjnl-2012-304038] [Cited by in Crossref: 175] [Cited by in F6Publishing: 138] [Article Influence: 17.5] [Reference Citation Analysis]
130 Hsieh YC, Lee KC, Wang YW, Yang YY, Hou MC, Huo TI, Lin HC. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS One 2018;13:e0208903. [PMID: 30540824 DOI: 10.1371/journal.pone.0208903] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
131 O’Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:402-412. [PMID: 23545523 DOI: 10.1038/nrgastro.2013.51] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
132 Saxena P, Lakhtakia S. Endoscopic ultrasound guided vascular access and therapy (with videos). Endosc Ultrasound. 2015;4:168-175. [PMID: 26374574 DOI: 10.4103/2303-9027.162994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Erice E, Llop E, Berzigotti A, Abraldes JG, Conget I, Seijo S, Reverter E, Albillos A, Bosch J, García-Pagán JC. Insulin resistance in patients with cirrhosis and portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1458-G1465. [PMID: 22492691 DOI: 10.1152/ajpgi.00389.2011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
134 Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W;  Practice Guidelines Committee of the American Association for the Study of Liver Diseases;  Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922-938. [PMID: 17879356 DOI: 10.1002/hep.21907] [Cited by in Crossref: 1135] [Cited by in F6Publishing: 905] [Article Influence: 75.7] [Reference Citation Analysis]
135 Miraglia R, Luca A, Maruzzelli L, Spada M, Riva S, Caruso S, Maggiore G, Gridelli B, Bosch J. Measurement of hepatic vein pressure gradient in children with chronic liver diseases. J Hepatol. 2010;53:624-629. [PMID: 20615572 DOI: 10.1016/j.jhep.2010.04.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
136 Garcia-Tsao G. Beta blockers in cirrhosis: The window re-opens. J Hepatol. 2016;64:532-534. [PMID: 26724557 DOI: 10.1016/j.jhep.2015.12.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
137 Kim SG, Larson JJ, Lee JS, Therneau TM, Kim WR. Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23:733-740. [PMID: 28187503 DOI: 10.1002/lt.24744] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
138 Merkel C. A short cut to predict the clinical response to beta-blocker therapy in cirrhosis? Journal of Hepatology 2009;51:268-70. [DOI: 10.1016/j.jhep.2009.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
139 Trebicka J, von Heydebrand M, Lehmann J, Tofteng F, Busk T, Jensen HL, Rohde J, Reiberger T, Mortensen C, Schierwagen R, Klein S, Møller S, Bendtsen F, Krag A. Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. Journal of Hepatology 2016;64:1265-73. [DOI: 10.1016/j.jhep.2016.01.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
140 Zipprich A, Loureiro-Silva MR, D'Silva I, Groszmann RJ. The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. Am J Physiol Gastrointest Liver Physiol 2008;295:G197-202. [PMID: 18497333 DOI: 10.1152/ajpgi.00190.2007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
141 Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S, Calleja JL, Bañares R, García-Pagán JC, Mesonero F, Bosch J; Ciberehd SportDiet Collaborative Group. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology 2017;65:1293-305. [PMID: 27997989 DOI: 10.1002/hep.28992] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 24.0] [Reference Citation Analysis]
142 Reichen J, Lebrec D. The future treatment of portal hypertension. Best Pract Res Clin Gastroenterol. 2007;21:191-202. [PMID: 17223505 DOI: 10.1016/j.bpg.2006.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
143 Thalheimer U, Bosch J, Patch D, Burroughs A. Improved survival with nonselective beta blockers. Hepatology 2008;48:2091-2. [DOI: 10.1002/hep.22600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
144 Blasco-Algora S, Masegosa-Ataz J, Alonso S, Gutiérrez ML, Fernández-Rodriguez C. Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol 2016;3:e000104. [PMID: 28074149 DOI: 10.1136/bmjgast-2016-000104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
145 Garcia-tsao G, Sanyal AJ, Grace ND, Carey WD; the Practice Guidelines Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Am J Gastroenterology 2007;102:2086-102. [DOI: 10.1111/j.1572-0241.2007.01481.x] [Cited by in Crossref: 219] [Cited by in F6Publishing: 165] [Article Influence: 14.6] [Reference Citation Analysis]
146 Boregowda U, Umapathy C, Halim N, Desai M, Nanjappa A, Arekapudi S, Theethira T, Wong H, Roytman M, Saligram S. Update on the management of gastrointestinal varices. World J Gastrointest Pharmacol Ther 2019; 10(1): 1-21 [PMID: 30697445 DOI: 10.4292/wjgpt.v10.i1.1] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 10] [Article Influence: 7.3] [Reference Citation Analysis]
147 Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther 2018;47:966-79. [PMID: 29388229 DOI: 10.1111/apt.14485] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
148 Stankovic Z, Jung B, Collins J, Russe MF, Carr J, Euringer W, Stehlin L, Csatari Z, Strohm PC, Langer M. Reproducibility study of four-dimensional flow MRI of arterial and portal venous liver hemodynamics: influence of spatio-temporal resolution. Magn Reson Med. 2014;72:477-484. [PMID: 24018798 DOI: 10.1002/mrm.24939] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
149 El-Karaksy HM, El-Koofy N, Mohsen N, Helmy H, Nabil N, El-Shabrawi M. Extrahepatic portal vein obstruction in Egyptian children. J Pediatr Gastroenterol Nutr 2015;60:105-9. [PMID: 25546337 DOI: 10.1097/MPG.0000000000000548] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
150 Kim HY, So YH, Kim W, Ahn DW, Jung YJ, Woo H, Kim D, Kim MY, Baik SK. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019;70:412-22. [PMID: 30389550 DOI: 10.1016/j.jhep.2018.10.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
151 Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23:1058-1069. [PMID: 28590564 DOI: 10.1002/lt.24794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
152 Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Van Gaal L, Michielsen P. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol. 2010;22:1449-1457. [PMID: 21389796 DOI: 10.1097/meg.0b013e32833f14a1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
153 Vorobioff JD. Hepatic venous pressure in practice: how, when, and why. J Clin Gastroenterol 2007;41 Suppl 3:S336-43. [PMID: 17975486 DOI: 10.1097/MCG.0b013e31814684d3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
154 Reverter E, Lozano JJ, Alonso C, Berzigotti A, Seijo S, Turon F, Baiges A, Martínez‐chantar ML, Mato JM, Martínez‐arranz I, La Mura V, Hernández‐gea V, Bosch J, García‐pagán JC. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver Int 2019;39:705-13. [DOI: 10.1111/liv.14042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
155 Ramsey ML, Sobotka LA, Hinton A, Reeves KC, Hanje AJ. Low Risk of Variceal Bleeding Among Subjects With Cirrhosis Treated With Electroconvulsive Therapy: A Nationwide Study. J ECT 2020;36:247-52. [DOI: 10.1097/yct.0000000000000704] [Reference Citation Analysis]
156 Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62:S121-S130. [PMID: 25920081 DOI: 10.1016/j.jhep.2015.01.003] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 18.7] [Reference Citation Analysis]
157 Mandorfer M, Hernández-gea V, Reiberger T, García-pagán JC. Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring? Curr Hepatology Rep 2019;18:174-86. [DOI: 10.1007/s11901-019-00469-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
158 Hobolth L, Møller S, Grønbæk H, Roelsgaard K, Bendtsen F, Feldager Hansen E. Carvedilol or propranolol in portal hypertension? A randomized comparison. Scandinavian Journal of Gastroenterology 2012;47:467-74. [DOI: 10.3109/00365521.2012.666673] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
159 Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med. 2017;15:200. [PMID: 29121925 DOI: 10.1186/s12916-017-0966-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
160 Wei G, Cao J, Huang P, An P, Badlani D, Vaid KA, Zhao S, Wang DQ, Zhuo J, Yin L, Frassetto A, Markel A, Presnyak V, Gandham S, Hua S, Lukacs C, Finn PF, Giangrande PH, Martini PGV, Popov YV. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3. J Hepatol 2021;74:1416-28. [PMID: 33340584 DOI: 10.1016/j.jhep.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
161 Magaz M, Baiges A, Hernández-Gea V. Precision medicine in variceal bleeding: Are we there yet? J Hepatol. 2020;72:774-784. [PMID: 31981725 DOI: 10.1016/j.jhep.2020.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
162 Taddei TH, Strazzabosco M. Hepatic Venous Pressure Gradient (HVPG), Serum Sodium (SNa), and Model of End-stage Liver Disease Score (MELD): Prognostic Significance and Correlations. Journal of Clinical Gastroenterology 2007;41:641-3. [DOI: 10.1097/mcg.0b013e318051741d] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
163 Cheung J, Zeman M, van Zanten SV, Tandon P. Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. Aliment Pharmacol Ther. 2009;30:577-588. [PMID: 19558563 DOI: 10.1111/j.1365-2036.2009.04075.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
164 Ripoll C. Hepatic venous pressure gradient and outcomes in cirrhosis. J Clin Gastroenterol. 2007;41 Suppl 3:S330-S335. [PMID: 17975485 DOI: 10.1097/mcg.0b013e318150d0f4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
165 Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol. 2017;67:399-411. [PMID: 28223101 DOI: 10.1016/j.jhep.2017.02.003] [Cited by in Crossref: 110] [Cited by in F6Publishing: 96] [Article Influence: 22.0] [Reference Citation Analysis]
166 Mazumder NR, Atiemo K, Kappus M, Cullaro G, Harinstein ME, Ladner D, Verna E, Lai J, Levitsky J. A Comprehensive Review of Outcome Predictors in Low MELD Patients. Transplantation 2020;104:242-50. [PMID: 31517785 DOI: 10.1097/TP.0000000000002956] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
167 Kumar S, Asrani SK, Kamath PS. Epidemiology, diagnosis and early patient management of esophagogastric hemorrhage. Gastroenterol Clin North Am. 2014;43:765-782. [PMID: 25440924 DOI: 10.1016/j.gtc.2014.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
168 Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47:1162-1169. [PMID: 29492989 DOI: 10.1111/apt.14576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
169 Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, Nuñez O, Matilla AM, Clemente G, Bañares R. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006;101:2269-74. [PMID: 17032192 DOI: 10.1111/j.1572-0241.2006.00743.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 91] [Article Influence: 7.6] [Reference Citation Analysis]
170 Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, Rouquet O, Dupuis E, Alric L, Vinel JP. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008;27:1261-1268. [PMID: 18397389 DOI: 10.1111/j.1365-2036.2008.03701.x] [Cited by in Crossref: 255] [Cited by in F6Publishing: 231] [Article Influence: 18.2] [Reference Citation Analysis]
171 Londoño MC, Abraldes JG, Altamirano J, Deacens T, Forns X. Clinical trial watch: reports from the Liver Meeting (American Association for the Study of Liver Diseases), Boston, November 2014. J Hepatol. 2015; Jan 31. [Epub ahead of print]. [PMID: 25646885 DOI: 10.1016/j.jhep.2015.01.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
172 Albillos A, Tejedor M. Secondary prophylaxis for esophageal variceal bleeding. Clin Liver Dis 2014;18:359-70. [PMID: 24679500 DOI: 10.1016/j.cld.2014.01.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
173 Hobolth L, Bendtsen F, Møller S. Indications for portal pressure measurement in chronic liver disease. Scandinavian Journal of Gastroenterology 2012;47:887-92. [DOI: 10.3109/00365521.2012.706827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
174 Roldán-Alzate A, Frydrychowicz A, Said A, Johnson KM, Francois CJ, Wieben O, Reeder SB. Impaired regulation of portal venous flow in response to a meal challenge as quantified by 4D flow MRI. J Magn Reson Imaging. 2015;42:1009-1017. [PMID: 25772828 DOI: 10.1002/jmri.24886] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
175 Miraglia R, Caruso S, Maruzzelli L, Spada M, Riva S, Sciveres M, Luca A. MDCT, MR and interventional radiology in biliary atresia candidates for liver transplantation. World J Radiol 2011; 3(9): 215-223 [PMID: 22007284 DOI: 10.4329/wjr.v3.i9.215] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
176 Hernández-Guerra M, García-Pagán JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol 2005;39:S131-7. [PMID: 15758648 DOI: 10.1097/01.mcg.0000155513.17715.f7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
177 Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-82. [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149] [Cited by in Crossref: 363] [Cited by in F6Publishing: 316] [Article Influence: 27.9] [Reference Citation Analysis]
178 Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6:e010902. [PMID: 27147389 DOI: 10.1136/bmjopen-2015-010902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
179 Maruyama H, Shiina S. Collaterals in portal hypertension: anatomy and clinical relevance. Quant Imaging Med Surg 2021;11:3867-81. [PMID: 34341755 DOI: 10.21037/qims-20-1328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Fiorucci S, Antonelli E, Tocchetti P, Morelli A. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovasc Drug Rev. 2004;22:135-146. [PMID: 15179450 DOI: 10.1111/j.1527-3466.2004.tb00136.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
181 Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48 Suppl 1:S68-S92. [PMID: 18304681 DOI: 10.1016/j.jhep.2008.01.021] [Cited by in Crossref: 190] [Cited by in F6Publishing: 154] [Article Influence: 13.6] [Reference Citation Analysis]
182 Stankovic Z, Csatari Z, Deibert P, Euringer W, Blanke P, Kreisel W, Abdullah Zadeh Z, Kallfass F, Langer M, Markl M. Normal and altered three-dimensional portal venous hemodynamics in patients with liver cirrhosis. Radiology. 2012;262:862-873. [PMID: 22357888 DOI: 10.1148/radiol.11110127] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
183 Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY. Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study. Hepatology. 2012;56:698-705. [PMID: 22378148 DOI: 10.1002/hep.25684] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
184 Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. 2013;33:1148-1157. [PMID: 23601333 DOI: 10.1111/liv.12172] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
185 Perumalswami PV, Schiano TD. The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci 2011;56:1266-81. [PMID: 21416246 DOI: 10.1007/s10620-011-1619-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
186 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
187 Schepke M, Kleber G, Nürnberg D, Willert J, Koch L, Veltzke-Schlieker W, Hellerbrand C, Kuth J, Schanz S, Kahl S. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2004;40:65-72. [PMID: 15239087 DOI: 10.1002/hep.20284] [Cited by in Crossref: 148] [Cited by in F6Publishing: 111] [Article Influence: 8.2] [Reference Citation Analysis]
188 Thalheimer U, Leandro G, Samonakis DN, Triantos CK, Patch D, Burroughs AK. Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Dig Liver Dis. 2005;37:601-608. [PMID: 15908290 DOI: 10.1016/j.dld.2005.02.009] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
189 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
190 González A, Augustin S, Pérez M, Dot J, Saperas E, Tomasello A, Segarra A, Armengol JR, Malagelada JR, Esteban R, Guardia J, Genescà J. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study. Hepatology 2006;44:806-12. [PMID: 17006916 DOI: 10.1002/hep.21343] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
191 Khan F, Tripathi D. Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions. World J Gastroenterol 2021; 27(44): 7612-7624 [PMID: 34908802 DOI: 10.3748/wjg.v27.i44.7612] [Reference Citation Analysis]
192 Turnes J, Hernández-Guerra M, Abraldes JG, Bellot P, Oliva R, García-Pagán JC, Bosch J. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology. 2006;43:34-41. [PMID: 16374847 DOI: 10.1002/hep.21000] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
193 Gouya H, Grabar S, Vignaux O, Saade A, Pol S, Legmann P, Sogni P. Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging. Eur Radiol 2016;26:1981-90. [DOI: 10.1007/s00330-015-3991-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
194 Giday SA, Clarke JO, Buscaglia JM, Shin EJ, Ko C, Magno P, Kantsevoy SV. EUS-guided portal vein catheterization: a promising novel approach for portal angiography and portal vein pressure measurements. Gastrointestinal Endoscopy 2008;67:338-42. [DOI: 10.1016/j.gie.2007.08.037] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
195 Turco L, Villanueva C, La Mura V, García-pagán JC, Reiberger T, Genescà J, Groszmann RJ, Sharma BC, Merkel C, Bureau C, Alvarado E, Abraldes JG, Albillos A, Bañares R, Peck-radosavljevic M, Augustin S, Sarin SK, Bosch J, García-tsao G. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology 2020;18:313-327.e6. [DOI: 10.1016/j.cgh.2019.05.050] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
196 Onali S, Kalafateli M, Majumdar A, Westbrook R, O'Beirne J, Leandro G, Patch D, Tsochatzis EA. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver Int. 2017;37:1334-1344. [PMID: 28296047 DOI: 10.1111/liv.13409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
197 Roldán-Alzate A, Frydrychowicz A, Niespodzany E, Landgraf BR, Johnson KM, Wieben O, Reeder SB. In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension. J Magn Reson Imaging. 2013;37:1100-1108. [PMID: 23148034 DOI: 10.1002/jmri.23906] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
198 Bosch J, Berzigotti A. Editorial: use of beta-blockers and of band ligation in preventing first and recurrent variceal bleeding-“real life” vs evidence-based decisions. Aliment Pharmacol Ther 2018;47:1222-3. [DOI: 10.1111/apt.14546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Huo TI, Wang YW, Yang YY, Lin HC, Lee PC, Hou MC, Lee FY, Lee SD. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int. 2007;27:498-506. [PMID: 17403190 DOI: 10.1111/j.1478-3231.2007.01445.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
200 de Souza AR, La Mura V, Reverter E, Seijo S, Berzigotti A, Ashkenazi E, García-Pagán JC, Abraldes JG, Bosch J. Patients whose first episode of bleeding occurs while taking a β-blocker have high long-term risks of rebleeding and death. Clin Gastroenterol Hepatol. 2012;10:670-66; quiz e58. [PMID: 22366180 DOI: 10.1016/j.cgh.2012.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
201 Rincón D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, Salcedo M, Matilla A, Senosiain M, Clemente G. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol. 2013;48:487-495. [PMID: 22871085 DOI: 10.3109/00365521.2012.711848] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
202 Ytting H, Møller S, Henrik Henriksen J, Larsen K, Bendtsen F. Prognosis in patients with cirrhosis and mild portal hypertension. Scandinavian Journal of Gastroenterology 2009;41:1446-53. [DOI: 10.1080/00365520600735720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
203 Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15:308. [PMID: 23314828 DOI: 10.1007/11894-0.12-0308-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Garcia-Pagán JC, Patch D. Trials and Tribulations: The Prevention of Variceal Rebleeding. Gastroenterology 2015;149:528-31. [PMID: 26226566 DOI: 10.1053/j.gastro.2015.07.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
205 Yang YY, Lee TY, Huang YT, Chan CC, Yeh YC, Lee FY, Lee SD, Lin HC. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int. 2012;32:48-57. [PMID: 22098317 DOI: 10.1111/j.1478-3231.2011.02651.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
206 Munoz SJ. The hepatorenal syndrome. Med Clin North Am. 2008;92:813-37, viii-ix. [PMID: 18570944 DOI: 10.1016/j.mcna.2008.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
207 Tay PWL, Xiao J, Tan DJH, Ng C, Lye YN, Lim WH, Teo VXY, Heng RRY, Yeow MWX, Lum LHW, Tan EXX, Kew GS, Lee GH, Muthiah MD. An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis. Front Med (Lausanne) 2021;8:693652. [PMID: 34422858 DOI: 10.3389/fmed.2021.693652] [Reference Citation Analysis]
208 Kumar M, Kainth S, Choudhury A, Maiwall R, Mitra LG, Saluja V, Agarwal PM, Shasthry SM, Jindal A, Bhardwaj A, Kumar G, Sarin SK. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int 2019;13:800-13. [DOI: 10.1007/s12072-019-09986-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
209 Villanueva C, Aracil C, Balanzó J. What to do with non-responders. In: Groszmann RJ, Bosch J, editors. Portal Hypertension in the 21st Century. Dordrecht: Springer Netherlands; 2004. pp. 337-48. [DOI: 10.1007/978-94-007-1042-9_34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
210 Reverter E, Mesonero F, Seijo S, Martínez J, Abraldes JG, Peñas B, Berzigotti A, Deulofeu R, Bosch J, Albillos A, García-Pagán JC. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. Am J Gastroenterol 2015;110:985-92. [PMID: 26077176 DOI: 10.1038/ajg.2015.185] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
211 Lee J, Chung MY. Does the model for end-stage liver disease score predict transfusion amount, acid-base imbalance, haemodynamic and oxidative abnormalities during living donor liver transplantation? J Int Med Res 2011;39:1773-82. [PMID: 22117978 DOI: 10.1177/147323001103900520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
212 Buechter M, Kersting S, Gerken G, Kahraman A. Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease. Sci Rep 2019;9:13577. [PMID: 31537822 DOI: 10.1038/s41598-019-49746-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Tseng Y, Li F, Wang J, Chen S, Jiang W, Shen X, Wu S. Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices. J Clin Ultrasound. 2018;46:442-449. [PMID: 30132919 DOI: 10.1002/jcu.22635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
214 Garcia-Tsao G. Can We Rely on Changes in HVPG in Patients with Cirrhosis? Hepatology 2021;74:2945-7. [PMID: 34569630 DOI: 10.1002/hep.32159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Ikenaga N, Liu SB, Sverdlov DY, Yoshida S, Nasser I, Ke Q, Kang PM, Popov Y. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 2015;185:325-34. [PMID: 25478810 DOI: 10.1016/j.ajpath.2014.10.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
216 Biecker E. Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol. 2013;2013:541836. [PMID: 27335828 DOI: 10.1155/2013/541836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
217 Yang J, Ge K, Chen L, Yang JL. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:1518-26. [PMID: 31094853 DOI: 10.1097/MEG.0000000000001442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
218 Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf)5:113-126. [PMID: 28533909 DOI: 10.1093/gastro/gox007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
219 Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-guerra M, Genesca J, Rodriguez M, Castellote J, García-pagán JC, Torres F, Calleja JL, Albillos A, Bosch J, Augustin S, Llop E, Arraez DM, Hernández Mesa G, Martinez J, Reverter E, Seijo S, Turon F, Miñana J, Buenestado J, Reñe JM, Navacués CA, Planas R, Morillas RM, Bellot P, Such J, Vergara M, Puente A, de la Pena J, Mera Calviño J, Rivas Moral L, Pavel O, Alvarado E, Ardevol A, Girbau A, Cachero A, Arnaiz JA, Berzigotti A, Pich J, Rios J, Saenz R, Millan L, Beleta H, Ramos N. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology 2016;150:1160-1170.e3. [DOI: 10.1053/j.gastro.2016.01.004] [Cited by in Crossref: 143] [Cited by in F6Publishing: 117] [Article Influence: 23.8] [Reference Citation Analysis]
220 Chen YI, Ghali P. Prevention and management of gastroesophageal varices in cirrhosis. Int J Hepatol. 2012;2012:750150. [PMID: 22577563 DOI: 10.1155/2012/750150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
221 Bhutta AQ, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, O'Leary JG, Acharya C, Banerjee D, Abraldes JG, Jones TM, Shaw J, Deng Y, Ciarleglio M, Bajaj JS. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther 2018;47:78-85. [PMID: 28994122 DOI: 10.1111/apt.14366] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
222 Tandon P, Saez R, Berzigotti A, Abraldes JG, Garcia-pagan JC, Bosch J. A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients. American Journal of Gastroenterology 2010;105:1917-21. [DOI: 10.1038/ajg.2010.196] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
223 Garcia-tsao G. Preventing the Development of Varices in Cirrhosis. Journal of Clinical Gastroenterology 2007;41:S300-4. [DOI: 10.1097/mcg.0b013e318157c63d] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
224 Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29:1189-1193. [PMID: 19508620 DOI: 10.1111/j.1478-3231.2009.02038.x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 119] [Article Influence: 10.9] [Reference Citation Analysis]
225 Ngwa T, Orman E, Gomez EV, Vuppalanchi R, Kubal C, Chalasani N, Ghabril M. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. BMC Gastroenterol 2020;20:4. [PMID: 31906860 DOI: 10.1186/s12876-019-1155-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
226 Reverter E, Blasi A, Abraldes JG, Martínez-Palli G, Seijo S, Turon F, Berzigotti A, Balust J, Bosch J, García-Pagán JC. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int 2014;34:16-25. [PMID: 23763484 DOI: 10.1111/liv.12229] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
227 Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; LiverHope Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol 2021;74:200-19. [PMID: 32896580 DOI: 10.1016/j.jhep.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
228 Aguirre-Reyes DF, Sotelo JA, Arab JP, Arrese M, Tejos R, Irarrazaval P, Tejos C, Uribe SA, Andia ME. Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension. Magn Reson Imaging 2015;33:970-7. [PMID: 26117696 DOI: 10.1016/j.mri.2015.06.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
229 Maleux G, Willems E, Fieuws S, Heye S, Vaninbroukx J, Laleman W, Cassiman D, Verslype C, Nevens F. Prospective study comparing different indirect methods to measure portal pressure. J Vasc Interv Radiol. 2011;22:1553-1558. [PMID: 22024115 DOI: 10.1016/j.jvir.2011.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
230 Yoon HM, Kim SY, Kim KM, Oh SH, Ko GY, Park Y, Lee JS, Jung AY, Cho YA. Liver Stiffness Measured by Shear-wave Elastography for Evaluating Intrahepatic Portal Hypertension in Children. J Pediatr Gastroenterol Nutr 2017;64:892-7. [PMID: 28107286 DOI: 10.1097/MPG.0000000000001517] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
231 Groszmann RJ, Ripoll C, Vorobioff J. Pre-Primary and Primary Prophylaxis: What Should We Do Next? In: de Franchis R, editor. Portal Hypertension V. Oxford: Wiley-Blackwell; 2011. pp. 66-74. [DOI: 10.1002/9781444393989.ch7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Monescillo A, Mart�nez-lagares F, Ruiz-del-arbol L, Sierra A, Guevara C, Jim�nez E, Marrero JM, Buceta E, S�nchez J, Castellot A, Pe�ate M, Cruz A, Pe�a E. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793-801. [DOI: 10.1002/hep.20386] [Cited by in Crossref: 322] [Cited by in F6Publishing: 217] [Article Influence: 17.9] [Reference Citation Analysis]
233 Bruha R, Jachymova M, Petrtyl J, Dvorak K, Lenicek M, Urbanek P, Svestka T, Vitek L. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol 2016; 22(12): 3441-3450 [PMID: 27022226 DOI: 10.3748/wjg.v22.i12.3441] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
234 Villanueva C, López-balaguer JM, Aracil C, Balanzó J. Reply. Journal of Hepatology 2005;42:147-8. [DOI: 10.1016/j.jhep.2004.08.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
235 Kawanaka H. Balloon-occluded retrograde transvenous obliteration: one step beyond obliteration of gastric varices. J Gastroenterol Hepatol 2012;27:3-4. [PMID: 22188023 DOI: 10.1111/j.1440-1746.2011.06954.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
236 Wadhawan M, Dubey S, Sharma BC, Sarin SK, Sarin SK. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child’s status. Dig Dis Sci. 2006;51:2264-2269. [PMID: 17080245 DOI: 10.1007/s10620-006-9310-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
237 Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am 2022;102:117-37. [PMID: 34800381 DOI: 10.1016/j.suc.2021.09.005] [Reference Citation Analysis]
238 La Mura V, Garcia‐guix M, Berzigotti A, Abraldes JG, García‐pagán JC, Villanueva C, Bosch J. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology 2020;72:1353-65. [DOI: 10.1002/hep.31125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
239 Sharma B, Sarin S. Hepatic Venous Pressure Gradient in Cirrhosis: Role in Variceal Bleeding, Non-bleeding Complications and Outcome. Asian Journal of Surgery 2006;29:113-9. [DOI: 10.1016/s1015-9584(09)60068-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
240 Senzolo M, Burra P, Cholongitas E, Lodato F, Marelli L, Manousou P, Patch D, Sturniolo GC, Burroughs AK. The transjugular route: the key hole to the liver world. Dig Liver Dis. 2007;39:105-116. [PMID: 17196894 DOI: 10.1016/j.dld.2006.06.038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
241 López-Méndez E, Uribe M. Beta blockers in portal hypertension. Are they really a good option? Ann Hepatol 2006;5:86-91. [PMID: 16807514 [PMID: 16807514 DOI: 10.1016/s1665-2681(19)32023-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
242 Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53:273-282. [PMID: 20570385 DOI: 10.1016/j.jhep.2010.03.013] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
243 Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr. 2013;125:200-219. [PMID: 23579878 DOI: 10.1007/s00508-013-0337-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
244 Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101:506-512. [PMID: 16542287 DOI: 10.1111/j.1572-0241.2006.00453.x] [Cited by in Crossref: 154] [Cited by in F6Publishing: 129] [Article Influence: 9.6] [Reference Citation Analysis]
245 Pérez-ayuso RM, Valderrama S, Espinoza M, Rollán A, Sánchez R, Otarola F, Medina B, Riquelme A. Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Annals of Hepatology 2010;9:15-22. [DOI: 10.1016/s1665-2681(19)31674-6] [Cited by in Crossref: 11] [Article Influence: 0.9] [Reference Citation Analysis]
246 Yoo JJ, Kim SG, Kim YS, Lee B, Jeong SW, Jang JY, Lee SH, Kim HS, Jun BG, Kim YD, Cheon GJ. Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: Propensity score matching analysis. Medicine (Baltimore) 2020;99:e18913. [PMID: 32000397 DOI: 10.1097/MD.0000000000018913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Ferrarese A, Zanetto A, Germani G, Burra P, Senzolo M. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol 2016; 8(24): 1012-1018 [PMID: 27648153 DOI: 10.4254/wjh.v8.i24.1012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
248 Kim TW, Kim HJ, Chon CU, Won HS, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? Clin Mol Hepatol 2012;18:203-12. [PMID: 22893871 DOI: 10.3350/cmh.2012.18.2.203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
249 Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology. 2010;51:1894-1896. [PMID: 20512984 DOI: 10.1002/hep.23710] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
250 Dib N, Oberti F, Calès P. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ 2006;174:1433-43. [PMID: 16682712 DOI: 10.1503/cmaj.051700] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
251 La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol. 2009;51:279-287. [PMID: 19501930 DOI: 10.1016/j.jhep.2009.04.015] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 6.8] [Reference Citation Analysis]
252 Barbu LA, Mărgăritescu ND, Şurlin MV. Diagnosis and Treatment Algorithms of Acute Variceal Bleeding. Curr Health Sci J 2017;43:191-200. [PMID: 30595875 DOI: 10.12865/CHSJ.43.03.02] [Reference Citation Analysis]
253 Wolf AT, Maurer R, Glickman J, Grace ND. Hepatic venous pressure gradient supplements liver biopsy in the diagnosis of cirrhosis. J Clin Gastroenterol 2008;42:199-203. [PMID: 18209592 DOI: 10.1097/01.mcg.0000225681.45088.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
254 Vorobioff J, Groszmann R. Portal Hypertension—Molecular Mechanisms. Liver Pathophysiology. Elsevier; 2017. pp. 435-49. [DOI: 10.1016/b978-0-12-804274-8.00034-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
255 Dib N, Konate A, Oberti F, Calès P. [Non-invasive diagnosis of portal hypertension in cirrhosis. Application to the primary prevention of varices]. Gastroenterol Clin Biol 2005;29:975-87. [PMID: 16435503 DOI: 10.1016/s0399-8320(05)88170-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
256 Funakoshi N, Ségalas-Largey F, Duny Y, Oberti F, Valats JC, Bismuth M, Daurès JP, Blanc P. Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: A meta-analysis. World J Gastroenterol 2010; 16(47): 5982-5992 [PMID: 21157975 DOI: 10.3748/wjg.v16.i47.5982] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
257 Song J, Huang J, Huang H, Liu S, Luo Y. Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension: A meta-analysis. Clin Res Hepatol Gastroenterol. 2018;42:216-226. [PMID: 29223365 DOI: 10.1016/j.clinre.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
258 Zhao Y, Guo L, Huang Q, Zhang R, Sun X, Zhao L, Li C, Nie Y, Sun G, Liu J. Observation of immediate and mid-term effects of partial spleen embolization in reducing hepatic venous pressure gradient. Medicine (Baltimore) 2019;98:e17900. [PMID: 31764786 DOI: 10.1097/MD.0000000000017900] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
259 Muntaner L, Altamirano JT, Augustin S, González A, Esteban R, Guardia J, Genescà J. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int. 2010;30:1123-1130. [PMID: 20536715 DOI: 10.1111/j.1478-3231.2010.02287.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
260 de-Madaria E, Palazón JM, Hernández FT, Sánchez-Paya J, Zapater P, Irurzun J, de España F, Pascual S, Such J, Sempere L, Carnicer F, García-Herola A, Valverde J, Pérez-Mateo M. Acute and chronic hemodynamic changes after propranolol in patients with cirrhosis under primary and secondary prophylaxis of variceal bleeding: a pilot study. Eur J Gastroenterol Hepatol 2010;22:507-12. [PMID: 20150817 DOI: 10.1097/MEG.0b013e32832ca06b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
261 Edwards C, Feng HQ, Reynolds C, Mao L, Rockey DC. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1311-G1317. [PMID: 18356534 DOI: 10.1152/ajpgi.00368.2007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
262 Zipprich A, Winkler M, Seufferlein T, Dollinger MM. Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther. 2010;32:1351-1356. [PMID: 21050237 DOI: 10.1111/j.1365-2036.2010.04484.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
263 Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-valdecasas J, Navasa M, García-pagán J, Bosch J. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study: Response to Propranolol in Liver Transplantation. Liver Transpl 2013;19:450-6. [DOI: 10.1002/lt.23614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
264 Ripoll C, Bañares R, Rincón D, Catalina M, Lo Iacono O, Salcedo M, Clemente G, Núñez O, Matilla A, Molinero L. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 2005;42:793-801. [DOI: 10.1002/hep.20871] [Cited by in Crossref: 151] [Cited by in F6Publishing: 130] [Article Influence: 8.9] [Reference Citation Analysis]
265 Bhutta AQ, Garcia-Tsao G. The Role of Medical Therapy for Variceal Bleeding. Gastrointest Endosc Clin N Am 2015;25:479-90. [PMID: 26142033 DOI: 10.1016/j.giec.2015.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
266 Garcia-pagán JC, Bosch J. Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction. Hepatology 2004;39:1746-7. [DOI: 10.1002/hep.20249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
267 Biecker E. Portal hypertension and gastrointestinal bleeding: Diagnosis, prevention and management. World J Gastroenterol 2013; 19(31): 5035-5050 [PMID: 23964137 DOI: 10.3748/wjg.v19.i31.5035] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
268 Huang YW, Lee CL, Yang SS, Fu SC, Chen YY, Wang TC, Hu JT, Chen DS. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol. 2016;111:976-985. [PMID: 27166128 DOI: 10.1038/ajg.2016.179] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
269 Xu X, Guo X, Tacke F, Shao X, Qi X. Use of nonselective β blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence. Ther Adv Chronic Dis 2019;10:2040622319862693. [PMID: 31321015 DOI: 10.1177/2040622319862693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
270 Vorobioff JD, Ferretti SE, Zangroniz P, Gamen M, Picabea E, Bessone FO, Reggiardo V, Diez AR, Tanno M, Cuesta C. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial. Am J Gastroenterol. 2007;102:2206-2213. [PMID: 17608776 DOI: 10.1111/j.1572-0241.2007.01390.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
271 Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis 2021;25:327-43. [PMID: 33838853 DOI: 10.1016/j.cld.2021.01.002] [Reference Citation Analysis]
272 Karadsheh Z, Allison H. Primary prevention of variceal bleeding: pharmacological therapy versus endoscopic banding. N Am J Med Sci. 2013;5:573-579. [PMID: 24350068 DOI: 10.4103/1947-2714.120791] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
273 Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, Burroughs AK. Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol. 2007;47:284-294. [PMID: 17561303 DOI: 10.1016/j.jhep.2007.05.001] [Cited by in Crossref: 242] [Cited by in F6Publishing: 196] [Article Influence: 16.1] [Reference Citation Analysis]
274 Garcia-tsao G. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. Nat Rev Gastroenterol Hepatol 2006;3:380-9. [DOI: 10.1038/ncpgasthep0523] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
275 Kotani K, Uchida-Kobayashi S, Yamamoto A, Kawamura E, Enomoto M, Higashiyama S, Kawabe J, Shiomi S, Tamori A, Kawada N. Per-rectal portal scintigraphy as an alternative measure of hepatic venous pressure gradient in chronic liver disease: A preliminary report. Clin Physiol Funct Imaging 2021;41:334-41. [PMID: 33843126 DOI: 10.1111/cpf.12703] [Reference Citation Analysis]
276 Stankovic Z, Allen BD, Garcia J, Jarvis KB, Markl M. 4D flow imaging with MRI. Cardiovasc Diagn Ther. 2014;4:173-192. [PMID: 24834414 DOI: 10.3978/j.issn.2223-3652.2014.01.02] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
277 Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology. 2007;133:2029-2036. [PMID: 18054573 DOI: 10.1053/j.gastro.2007.10.028] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
278 Rössle M, Blanke P, Fritz B, Schultheiss M, Bettinger D. Free Hepatic Vein Pressure Is Not Useful to Calculate the Portal Pressure Gradient in Cirrhosis: A Morphologic and Hemodynamic Study. Journal of Vascular and Interventional Radiology 2016;27:1130-7. [DOI: 10.1016/j.jvir.2016.03.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
279 Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643-653. [PMID: 24076364 DOI: 10.1016/j.jhep.2013.09.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 9.2] [Reference Citation Analysis]
280 Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, Riggio O, Venditti M. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35:362-369. [PMID: 24836902 DOI: 10.1111/liv.12593] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 8.1] [Reference Citation Analysis]
281 Tey TT, Gogna A, Irani FG, Too CW, Lo HG, Tan BS, Tay KH, Lui HF, Chang PE. Application of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhotics. Singapore Med J 2016;57:132-7. [PMID: 26996384 DOI: 10.11622/smedj.2016054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
282 Kim JH, Park SW, Jung JH, Park DH, Bang CS, Park CH, Park JW, Park JG. Bedside risk-scoring model for predicting 6-week mortality in cirrhotic patients undergoing endoscopic band ligation for acute variceal bleeding. J Gastroenterol Hepatol 2021;36:1935-43. [PMID: 33538357 DOI: 10.1111/jgh.15426] [Reference Citation Analysis]
283 Tandon P, Inayat I, Tal M, Spector M, Shea M, Groszmann RJ, Garcia-Tsao G. Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clin Gastroenterol Hepatol. 2010;8:546-549. [PMID: 20144739 DOI: 10.1016/j.cgh.2010.01.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
284 Kim DH, Park JY. Prevention and management of variceal hemorrhage. Int J Hepatol 2013;2013:434609. [PMID: 23606973 DOI: 10.1155/2013/434609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
285 Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56:696-703. [PMID: 21767510 DOI: 10.1016/j.jhep.2011.07.005] [Cited by in Crossref: 215] [Cited by in F6Publishing: 175] [Article Influence: 19.5] [Reference Citation Analysis]
286 Grangé J. Comment traiter et prévenir l’infection du liquide d’ascite ? Gastroentérologie Clinique et Biologique 2004;28:278-86. [DOI: 10.1016/s0399-8320(04)95267-0] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
287 Zhang F, Duan X, Zhang M, Li Z, He Q, Wang Y, Miao C, Zhong W, Zou X, Zhuge Y. Influence of CYP2D6 and β2-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis. J Gastroenterol Hepatol 2016;31:829-34. [PMID: 26489037 DOI: 10.1111/jgh.13198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
288 Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, Bosch J. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007;46:1040-1046. [PMID: 17335931 DOI: 10.1016/j.jhep.2007.01.020] [Cited by in Crossref: 150] [Cited by in F6Publishing: 130] [Article Influence: 10.0] [Reference Citation Analysis]
289 Gonzalez-suarez B, Guarner C, Villanueva C, Minana J, Soriano G, Gallego A, Sainz S, Torras X, Cusso X, Balanzo J. Pharmacologic treatment of portal hypertension in the prevention of community-acquired spontaneous bacterial peritonitis: . European Journal of Gastroenterology & Hepatology 2006;18:49-55. [DOI: 10.1097/00042737-200601000-00009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
290 Garcia-tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding-Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology 2008;47:1764-72. [DOI: 10.1002/hep.22273] [Cited by in Crossref: 180] [Cited by in F6Publishing: 138] [Article Influence: 12.9] [Reference Citation Analysis]
291 Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther. 2008;28:178-186. [PMID: 18462268 DOI: 10.1111/j.1365-2036.2008.03729.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
292 Parikh S. Hepatic Venous Pressure Gradient: Worth Another Look? Dig Dis Sci. 2009;54:1178-1183. [PMID: 18975087 DOI: 10.1007/s10620-008-0491-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
293 De BK, Dutta D, Som R, Biswas PK, Pal SK, Biswas A. Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial. World J Gastroenterol 2008; 14(12): 1908-1913 [PMID: 18350631 DOI: 10.3748/wjg.14.1908] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
294 Addley J, Tham TC, Cash WJ. Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc 2012; 4(7): 281-289 [PMID: 22816007 DOI: 10.4253/wjge.v4.i7.281] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
295 Triantos C, Goulis J, Burroughs AK. Portal Hypertensive Bleeding. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 562-602. [DOI: 10.1002/9781444314403.ch36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
296 Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology. 2007;46:1208-1217. [PMID: 17654489 DOI: 10.1002/hep.21785] [Cited by in Crossref: 137] [Cited by in F6Publishing: 109] [Article Influence: 9.1] [Reference Citation Analysis]
297 Wang YW, Huo TI, Yang YY, Hou MC, Lee PC, Lin HC, Lee FY, Chi CW, Lee SD. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol. 2007;41:706-712. [PMID: 17667056 DOI: 10.1097/mcg.0b013e31802dabb3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
298 Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch D, O’Beirne J, Rolles K, Burroughs AK. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int. 2009;22:172-181. [PMID: 18786149 DOI: 10.1111/j.1432-2277.2008.00744.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
299 Mura VL, Nicolini A, Tosetti G, Primignani M. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol 2015; 7(4): 688-695 [PMID: 25866605 DOI: 10.4254/wjh.v7.i4.688] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
300 Fizanne L, Régenet N, Wang J, Oberti F, Moal F, Roux J, Gallois Y, Michalak S, Calès P. Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension. Hepatol Int. 2008;2:457-464. [PMID: 19669320 DOI: 10.1007/s12072-008-9070-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
301 Vorobioff JD, Groszmann RJ. Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage. Annals of Hepatology 2013;12:22-9. [DOI: 10.1016/s1665-2681(19)31381-x] [Cited by in Crossref: 12] [Article Influence: 1.3] [Reference Citation Analysis]
302 Madsen BS, Havelund T, Krag A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther 2013;30:659-70. [PMID: 23881723 DOI: 10.1007/s12325-013-0044-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
303 Huet PM, Pomier-Layrargues G. The hepatic venous pressure gradient: "remixed and revisited". Hepatology 2004;39:295-8. [PMID: 14767980 DOI: 10.1002/hep.20070] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
304 Villanueva C, Graupera I, Aracil C, Alvarado E, Miñana J, Puente Á, Hernandez-Gea V, Ardevol A, Pavel O, Colomo A, Concepción M, Poca M, Torras X, Reñe JM, Guarner C. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. Hepatology 2017;65:1693-707. [PMID: 28100019 DOI: 10.1002/hep.29056] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 8.4] [Reference Citation Analysis]
305 Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, Ferguson JW. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015;64:1111-9. [DOI: 10.1136/gutjnl-2013-306502] [Cited by in Crossref: 112] [Cited by in F6Publishing: 82] [Article Influence: 14.0] [Reference Citation Analysis]
306 Anastasiou J, Berzin TM. Endoscopic Ultrasound-Guided Vascular Interventions: From Diagnosis to Treatment. Saudi J Med Med Sci. 2018;6:61-67. [PMID: 30787823 DOI: 10.4103/sjmms.sjmms_131_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]